Conference Track

Metabolic Complications & Lipodystrophy

Source: CCO Independent Conference Coverage of the 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Uridine Prevents and Reverses In Vitro Adipocyte Abnormalities Related to NRTI exposure
Tenofovir Plus Emtricitabine Superior to Fixed-Dose Zidovudine/Lamivudine, Each With Efavirenz, in Antiretroviral Therapy-Naive Patients
HIV-1 Disease, Not HAART Use, Linked to Bone Demineralization
Switch From Stavudine to Tenofovir Reverses Lipid Abnormalities, Lipodystrophy
Patterns of Lipid Changes Associated With Different Initial Antiretroviral Regimens
No Progression of Bone Mineral Density Loss or Lipodystrophy After 4 Years of Sustained Virologic Response with Tenofovir, Lamivudine, and Efavirenz
Metabolic Syndrome More Common in HIV-Infected Men Than in Uninfected Men in MACS
Switch From Stable PI-Based to Atazanavir-Based Regimen Reduces Risk of Viral Rebound and Improves Lipid Profile
Factors Associated With Diabetes Mellitus in D:A:D Study
Antiretroviral Treatment Interruption Associated With Improvement in Bone Mineral Density, But No Morphologic Changes
Switch to Atazanavir Improves Lipid Profile in Patients on HAART
Replacement of Thymidine NRTI With Tenofovir or Abacavir Significantly Improves Facial Lipoatrophy
Similar Virologic Activity, But Differing Adverse Effects and Metabolic Profiles of NRTI-Based and NRTI-Sparing Regimens

Expert Analysis

Metabolic Complications and Lipodystrophy

Program Director: John P. Phair, MD

Faculty:

Judith S. Currier, MD, MSc
Sally Hodder, MD
William G. Powderly, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount switching strategies for the prevention of lipoatrophy and dyslipidemia.
Review new findings regarding the effect of HIV disease and treatment on bone mineral density.
Describe the influence of HIV disease and treatment on metabolic conditions.

CME CREDIT INFORMATION

Release Date: 09/30/05

Expiration Date: 09/29/06

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing CE credits

Pharmacists: 1.3 contact hours (0.13 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.